{
    "nctId": "NCT00461136",
    "officialTitle": "An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy",
    "inclusionCriteria": "* Male and/or female patients from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria).\n* Incipient and established diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day).\n* Glomerular filtration rate (GFR) \u2265 40 ml/min (estimated using Modification of Diet in Renal Disease (MDRD) formula) in the last 4 months.\n* Female patients must be postmenopausal or must have had a bilateral oophorectomy or must have been surgically sterilized or hysterectomized at least 6 months prior to screening.\n* To be eligible patients must fulfill the following criteria: Patients on ongoing hypertensive therapy must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day -1).; Newly diagnosed hypertensive patients must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1).\n* Patients must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 ( Day -1).\n* Patients must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.\n* Oral body temperature within the range 35.0-37.5 \u00b0C\n* Able to provide written informed consent prior to study participation. .\n* Able to communicate well with the investigator and comply with the requirements of the study.\n* Must have minimum age of 30 Years\n* Must have maximum age of 80 Years",
    "exclusionCriteria": "* Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)\n* Acetylsalicyclic acid (ASA) treatment \\>1g/day or regular use of Non steroidal anti-inflammatory drug (NSAIDs)\n* Kidney disease not caused by diabetes or hypertension\n* Serum potassium \\< 3.5 or \\> 5.1 mEq/L\n* GFR \\< 40 ml/min/1.73m2 as measured by the MDRD formula\n* Serum albumin \\< 2.0mg/dL\n* History of hypertensive encephalopathy or cerebrovascular accident at any time prior to Visit1.\n* Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV)\n* History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1\n* Second or third degree heart block without a pacemaker\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia\n* Clinically significant valvular heart disease\n* Type 1 diabetes mellitus\n* Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) \\>11 %)\n* History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years\n* Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.\n* Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.\n* Significant illness within the two weeks prior to dosing.\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:\n\nHistory of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection\n\n-Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1 Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.\n\nAny history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt\n\n* Current treatment with cholestyramine or cholestipol resins\n* History of immunocompromise, including a positive HIV test result.\n* History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.\n* History of drug or alcohol abuse within the 12 months prior to dosing.\n* Persons directly involved in the execution of this protocol.\n* Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety\n* History of noncompliance to medical regimens or unwillingness to comply with the study protocol\n* Known or suspected contraindications to the study medications, including history of allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics or other sulfonamide derived drug\n* Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study\n* Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol.\n* Patients who previously participated in any Aliskiren study.\n* Pregnant or nursing woman.\n\nOther protocol-defined inclusion/exclusion criteria may apply"
}